

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 7, 2002

CRYOLIFE, INC.
(Exact name of registrant as specified in its charter)

Florida
(State or other jurisdiction of incorporation)

1-13165
(Commission File Number)

59-2417093
(IRS Employer Identification No.)

1655 Roberts Boulevard N.W., Kennesaw, Georgia 30144
(Address of principal executive offices, including zip code)

(770) 419-3355
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Item 4. Changes in Registrant's Certifying Accountant.

On May 7, 2002, CryoLife, Inc. ("CryoLife") engaged Deloitte & Touche, LLP ("Deloitte") as its independent auditors. The decision to engage Deloitte was recommended by the Audit Committee and was approved by the Board of Directors of CryoLife. The engagement will be effective immediately. Deloitte replaces the firm of Arthur Andersen LLP as independent auditors of CryoLife. On April 9, 2002, CryoLife dismissed Arthur Andersen as its independent auditors.

Neither CryoLife nor anyone engaged on its behalf has consulted with Deloitte during CryoLife's two most recently completed fiscal years or during its current fiscal year with regard to either: (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on CryoLife's financial statements; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

CryoLife hereby incorporates by reference herein the information set forth in its press release dated May 7, 2002, a copy of which is attached hereto as Exhibit 99.1

Item 7. Financial Statements and Exhibits.

(a) Financial Statements.

Not applicable.

(b) Pro Forma Financial Information.

Not applicable.

(c) Exhibits.

Exhibit Number	Description
99.1	Press Release dated May 7, 2002

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CRYOLIFE, INC.

Date: May 10, 2002

By: /s/ D. Ashley Lee

Name: D. Ashley Lee
Title: Vice President, Chief
Financial Officer

3

EXHIBIT INDEX

Exhibit Number	Description	Page
99.1	Press Release dated May 7, 2002	

1461480

[GRAPHIC OMITTED]

NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact: D. Ashley Lee
Vice President, Chief Financial Officer
(800) 438-8285

CRYOLIFE, INC. APPOINTS NEW ACCOUNTING FIRM

Atlanta, GA ... (May 7, 2002)... CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of cryopreserved and tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, announced that its Board of Directors has appointed the accounting firm of Deloitte & Touche, LLP as the Company's independent auditors.

Founded in 1984, CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) surgical adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada and Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft(R) heart valve and the SynerGraft vascular graft, the world's first tissue-engineered heart valve and vascular replacement, respectively, and the CryoLife-O'Brien(R) and CryoLife-Ross(R) stentless porcine heart valves, which are CE marked for distribution within the European Community. The human heart valves and vascular grafts processed by CryoLife using the SynerGraft technology are distributed in the U.S. under the trade names of CryoValve(R)SG and CryoVein(R)SG, respectively.

For additional information about the company, visit CryoLife's web site:

<http://www.cryolife.com> -END-

1461480